Cellectar Biosciences Inc. receives second-phase of NCI SBIR award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cellectar Biosciences Inc. received the second phase of an NCI Fast-Track Small Business Innovation Research contract award of $2 million to support funding of a phase II study of the company’s lead product candidate, CLR 131, for the potential treatment of hematologic malignancies, including multiple myeloma.

The award will help fund a multi-center, open label study. The first phase of the NCI SBIR contract was focused on the pre-clinical development of CLR 125.

YOU MAY BE INTERESTED IN

The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login